MannKind Formulations & the Buckets
Nov 5, 2017 22:34:22 GMT -5
sportsrancho, sla55, and 4 more like this
Post by mango on Nov 5, 2017 22:34:22 GMT -5
In this thread we'll take a look at the MannKind Bucket List and the corresponding MannKind Technosphere formulations. Maybe some speculation too.
• The MannKind Bucket List
• MannKind Fact Sheet
Product Pipeline:
MKC253
MKC253 is a Technosphere formulation of GLP-1 (glucagon-like peptide). In initial clinical studies, MKC253 showed a lack of the characteristic adverse events, like nausea and vomiting, that are frequently associated with long-acting GLP-1 analogs. Results from a phase 1 trial support the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with Type 2 diabetes.
MKC180
MKC180 is a novel Technosphere formulation of a natural hormone to control satiety for addressing obesity. The product is an inhaled oxyntomodulin intended for use at mealtime. In nonclinical studies, MKC180 demonstrated a dose dependent decrease in food consumption up to six hours after pulmonary administration and was superior to both placebo and an IV infusion of oxyntomodulin.
MKC204
MKC204 is an IRE-1 alpha inhibitor with potential application in the treatment of multiple myeloma. IRE-1 alpha is a protein important in the regulation of the Unfolded Protein Response (UPR) cascade. Additional potential indications for UPR pathway inhibitors include autoimmune diseases, cardiovascular diseases and neurodegenerative disorders.
Technosphere Technology:
MannKind's proprietary Technosphere® Technology platform is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. The technology enables rapid systemic delivery of a broad range of therapeutics agents, including proteins, peptides and small molecule drugs via oral inhalation to the deep lung utilizing MannKind's proprietary inhalers. In addition to the compounds highlighted previously, MannKind currently has a variety of Technosphere formulations in development to treat conditions such as osteoporosis, hypoglycemia, migraine and pain associated with irritable bowel syndrome.
• Comments
1) First I want to bring IRE-1α to light. Numerous patents by MannKind have been published by on IRE-1 alpha inhibitors. This therapy could potentially help treat well over 100 conditions: b cell autoimmune diseases, viral infections, neurodegenerative disorders, cancers...diabetes falls under this. We're talking about a potential life saving (curing?) therapy here. On October 26, 2017 a paper was published, Autophagy and the Unfolded Protein Response Promote Pro-fibrotic Effects of TGFβ1 in Human Lung Fibroblasts. and J. Patterson from MannKind Corporation was a listed author. The paper involves an IRE-1a inhibitor.
2) MannKind has GLP-1 in Bucket # 3. We have seen some patents lately by MannKind published on this. We also know MannKind's GLP-1 formulation is quite promising: MKC253 is a Technosphere formulation of GLP-1 (glucagon-like peptide). In initial clinical studies, MKC253 showed a lack of the characteristic adverse events, like nausea and vomiting, that are frequently associated with long-acting GLP-1 analogs. Results from a phase 1 trial support the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with Type 2 diabetes[.
This doesn't interest me enough to go on from here. Perhaps Dr. Fonzo whoever would be interested in this.
3) Up next, oxyntomodulin. We know this is very promising, and is in Bucket #3. We also know MannKind's formulation is more than likely superior to anything else out there. MKC180 demonstrated a dose dependent decrease in food consumption up to six hours after pulmonary administration and was superior to both placebo and an IV infusion of oxyntomodulin.
4) TPI-2088 in Bucket #4 is a new molecule for treating pain. We see MannKind's prior work with a tetrapeptide called, TPI-23 in this paper:
abstracts.aaps.org/Verify/aaps2013/postersubmissions/T3083.pdf
I imagine TPI-2088 was also discovered by Torrey Pines just as TPI-23 was.
5) I wonder when we will here more about Receptor Life Sciences? Their therapeutic focuses cover/overlap with some of "MannKind's".
• MannKind IRE-1 alpha inhibitor granted patent from this year:
patents.justia.com/patent/9546149
• MannKind Fact Sheet:
www.mannkindcorp.com/Collateral/Documents/English-US/MannKind%20Fact%20Sheet.pdf
* I realize this MannKind Fact Sheet is old but it is relevant and a good source for what might be going on in these Buckets.
• The MannKind Bucket List
• MannKind Fact Sheet
Product Pipeline:
MKC253
MKC253 is a Technosphere formulation of GLP-1 (glucagon-like peptide). In initial clinical studies, MKC253 showed a lack of the characteristic adverse events, like nausea and vomiting, that are frequently associated with long-acting GLP-1 analogs. Results from a phase 1 trial support the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with Type 2 diabetes.
MKC180
MKC180 is a novel Technosphere formulation of a natural hormone to control satiety for addressing obesity. The product is an inhaled oxyntomodulin intended for use at mealtime. In nonclinical studies, MKC180 demonstrated a dose dependent decrease in food consumption up to six hours after pulmonary administration and was superior to both placebo and an IV infusion of oxyntomodulin.
MKC204
MKC204 is an IRE-1 alpha inhibitor with potential application in the treatment of multiple myeloma. IRE-1 alpha is a protein important in the regulation of the Unfolded Protein Response (UPR) cascade. Additional potential indications for UPR pathway inhibitors include autoimmune diseases, cardiovascular diseases and neurodegenerative disorders.
Technosphere Technology:
MannKind's proprietary Technosphere® Technology platform is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. The technology enables rapid systemic delivery of a broad range of therapeutics agents, including proteins, peptides and small molecule drugs via oral inhalation to the deep lung utilizing MannKind's proprietary inhalers. In addition to the compounds highlighted previously, MannKind currently has a variety of Technosphere formulations in development to treat conditions such as osteoporosis, hypoglycemia, migraine and pain associated with irritable bowel syndrome.
• Comments
1) First I want to bring IRE-1α to light. Numerous patents by MannKind have been published by on IRE-1 alpha inhibitors. This therapy could potentially help treat well over 100 conditions: b cell autoimmune diseases, viral infections, neurodegenerative disorders, cancers...diabetes falls under this. We're talking about a potential life saving (curing?) therapy here. On October 26, 2017 a paper was published, Autophagy and the Unfolded Protein Response Promote Pro-fibrotic Effects of TGFβ1 in Human Lung Fibroblasts. and J. Patterson from MannKind Corporation was a listed author. The paper involves an IRE-1a inhibitor.
2) MannKind has GLP-1 in Bucket # 3. We have seen some patents lately by MannKind published on this. We also know MannKind's GLP-1 formulation is quite promising: MKC253 is a Technosphere formulation of GLP-1 (glucagon-like peptide). In initial clinical studies, MKC253 showed a lack of the characteristic adverse events, like nausea and vomiting, that are frequently associated with long-acting GLP-1 analogs. Results from a phase 1 trial support the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with Type 2 diabetes[.
This doesn't interest me enough to go on from here. Perhaps Dr. Fonzo whoever would be interested in this.
3) Up next, oxyntomodulin. We know this is very promising, and is in Bucket #3. We also know MannKind's formulation is more than likely superior to anything else out there. MKC180 demonstrated a dose dependent decrease in food consumption up to six hours after pulmonary administration and was superior to both placebo and an IV infusion of oxyntomodulin.
4) TPI-2088 in Bucket #4 is a new molecule for treating pain. We see MannKind's prior work with a tetrapeptide called, TPI-23 in this paper:
abstracts.aaps.org/Verify/aaps2013/postersubmissions/T3083.pdf
I imagine TPI-2088 was also discovered by Torrey Pines just as TPI-23 was.
5) I wonder when we will here more about Receptor Life Sciences? Their therapeutic focuses cover/overlap with some of "MannKind's".
• MannKind IRE-1 alpha inhibitor granted patent from this year:
patents.justia.com/patent/9546149
• MannKind Fact Sheet:
www.mannkindcorp.com/Collateral/Documents/English-US/MannKind%20Fact%20Sheet.pdf
* I realize this MannKind Fact Sheet is old but it is relevant and a good source for what might be going on in these Buckets.
